绥美凯治疗艾滋病疗效好吗？

It is a drug that can prevent the HIV virus from entering cells and is the most commonly used drug in the treatment of AIDS. AIDS is a very harmful disease. You all know this. So far, it has been more than 40 years since the discovery of AIDS. The treatment effect of AIDS has never been particularly ideal. Until scientists developed Suimeike, the control effect of HIV has been good, and drug resistance is relatively rare. Is Suimeikai effective in treating AIDS?

Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance.

Suimeikai is a core drug based on DTG, an integrase inhibitor. In the real world, antiviral treatment-naïve patients treated with DTG are better than RAL (Ascent), DRV/r (darunavir), and EFV (efavirenz). ) and ATV/r (atazanavir) have a lower proportion of central nervous system-related (CNS) adverse events. Therefore, the drug safety of Trimeq, which is based on DTG integrase inhibitors, has proven to be controllable.

It is a drug for the treatment of AIDS. Trimecavir is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Recommended related hot articles: /newsDetail/71821.html